• Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) analog, is a novel immunosuppressant drug that induces lymphopenia by preventing emergence of lymphocytes from lymph nodes. Fingolimod is a sphingosine-1-phosphate receptor 1 modulator and is in phase III clinical trials for relapsing-remitting multiple sclerosis. Chiba, K., et al. \"Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.\" Cell Mol. Immunol. 3: 11-19 (2006). Dev, K.K., et al. \"Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.\" Pharmacol. Ther. 117: 77-93 (2008).
• Suppresses allotransplant rejections and autoimmune disorders in different animal models. Kunzendorf, U., et al. \"FTY720—the first compound of a new promising class of immunosuppressive drugs.\" Nephrol. Dial. Transplant. 19: 1677-1681 (2004).
• Fingolimod appears to promote the survival of human and animal allografts by sequestering T lymphocytes within peripheral lymphoid tissue. Evidence for this mechanism of sequestration includes: (1) fingolimod drives T lymphocytes into peripheral lymph nodes in a chemokine dependent manner; (2) fingolimod downregulates sphingosine 1-phosphate receptors (S1PRs) on the T lymphocyte surface, preventing it from migrating along a S1P gradient; and (3) fingolimod blocks stromal gates on the abluminal side of the lymphatic endothelium. Yopp, A.C., et al. \"Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants.\" Clin. Transplant. 20: 788-795 (2006).
• Fingolimod, as the hydrochloride salt, is the active ingredient in the drug sold under the trade names Gilenya® and Gilenia® by Novartis AG. This drug is currently approved in at least one country for use in patients with relapsing forms of multiple sclerosis. NOTE: THE FINGOLIMOD, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC Laboratories IS NOT GILENYA® nor GILENIA® AND IS NOT FOR HUMAN USE. Gilenya® is a registered trademark of Novartis AG. LC Laboratories is not affiliated with Novartis AG, and the fingolimod hydrochloride research compound sold by LC Laboratories is not manufactured by Novartis AG.
• Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
• Not available in some countries; not available to some institutions; not available for some uses.
• Please see also our other standard immunosuppressant products:A-1040 AscomycinC-6000 Cyclosporin AE-4040 EverolimusF-4900 FK-506P-6040 PimecrolimusR-5000 RapamycinT-8040 TemsirolimusT-1377 Tofacitinib, Free BaseZ-9040 Zotarolimus

Related Terms:

Storage

Solubility

Up to 25 µL of a solution of 13.8 mg/mL (40 mM) fingolimod-HCl in 100% DMSO can be diluted into 5 mL of plain water without precipitation, giving a final concent.Disposal